Topoisomerase II inhibitor induced leukemia in a patient with AIDS.
Nabil
S
S
Department of Internal Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, USA.
Thomas
F
F
Douglas
R
R
Michael
B
B
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D018451:Homosexuality, Male; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000188:drug therapy; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000188:drug therapy; D059005:Topoisomerase II Inhibitors
D059005:Topoisomerase II Inhibitors; D003561:Cytarabine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate; D015255:Idarubicin